Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R; GIMEMA group. Pane F, et al. Among authors: quintarelli c. Leukemia. 2005 Apr;19(4):628-35. doi: 10.1038/sj.leu.2403683. Leukemia. 2005. PMID: 15744351 Free article. Clinical Trial.
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.
Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F. Quintarelli C, et al. Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15. Leuk Res. 2014. PMID: 24280282
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F. Esposito N, et al. Among authors: quintarelli c. Blood. 2011 Sep 29;118(13):3634-44. doi: 10.1182/blood-2011-03-341073. Epub 2011 Aug 5. Blood. 2011. PMID: 21821701 Free article.
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P. Kaeda J, et al. Among authors: quintarelli c. Leuk Lymphoma. 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. Epub 2015 Jan 23. Leuk Lymphoma. 2015. PMID: 25363400
109 results